Fulltext Search
363 Sales as a Health Care M&A Tool, Part 2 - Pros and Cons for Buyers and Sellers

 

Over the summer, we wrote about why health care companies may want to consider buying assets out of bankruptcy, taking advantage of the Bankruptcy Code Section 363 sale process (a “363 Sale”). We are back with our second post, to provide more detail to the process and discuss some pros and cons of 363 Sales.

USA, Insolvency & Restructuring, Litigation, Mintz, Due diligence, Non-disclosure agreement, Title 11 of the US Code
363 Sales as a Health Care M&A Tool, Part 1 - Overview

This two-part blog series discusses why buyers looking to make strategic purchases in the health care industry might want to take advantage of the Bankruptcy Code Section 363 sale process (363 Sale) and the pros and cons of buying assets out of bankruptcy through a 363 Sale.

USA, Healthcare & Life Sciences, Insolvency & Restructuring, Mintz, Due diligence, Coronavirus
Financial Services: Preparations for a ‘No-Deal’ Brexit

The Irish Government is planning to take measures in the areas of settlement finality, insurance, and insurance distribution in the event of a 'no-deal Brexit'. The relevant measures are set out in Parts 7 and 8 of the Withdrawal of the United Kingdom from the European Union (Consequential Provisions) Bill 2019 (the “Withdrawal Bill”), which was published on 22 February 2019. These measures are in addition to a number of measures already taken at EU level.

Settlement Finality

European Union, United Kingdom, Banking, Capital Markets, Derivatives, Insolvency & Restructuring, Insurance, Public, McCann FitzGerald LLP, Brexit, Central securities depository, Financial Conduct Authority (UK), European Commission, Central Bank of Ireland, European Securities and Markets Authority